Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.

Latest From Bowman Cox

US Supply Chain In Brief: White House Aims To Deliver With Block Stowing And Industrial Base Expansion

Biden administration works to expedite medical supplies and expand medical countermeasures production, while US FDA's DSCSA anti-counterfeiting paperwork burden estimate surges.

Distribution Manufacturing

Defense Secretary Asked To Brief US Congress On Pharmaceutical Supply Chain Security

Congress seeks advice from Defense Department on procuring active pharmaceutical ingredients domestically for national security purposes as efforts to identify areas of concern get underway.

Manufacturing Ingredients

The Quality Lowdown: Pandemic Site Evaluation Creativity On Display As COVID Clampdown Returns

With a virtual visit to SciVac in Israel, a belated Revance site inspection in California and two weeks at a Dr. Reddy’s site in India, the US FDA finds ways to overcome travel restrictions in its efforts to oversee drug manufacturing quality.

Drug Approval Standards Quality

How Post-Approval GMP Challenges Cooled Novo Nordisk’s Blazing Wegovy Launch

Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.

Launches Quality

US FDA Limits GMP Exemption For ‘N of 1’ Investigational New Drugs

Agency drafts guidance on how to apply requirements for chemistry, manufacturing and controls, and for good manufacturing practices, to bespoke antisense nucleotides.

Personalized Medicine Drug Approval Standards

Achieving A Resilient Flu Vaccine Supply Chain Requires Retooling Most Of The Links

Expert panel draws lessons from COVID-19 in pressing for new manufacturing technologies, greater global coordination, more resilient supply chains and trained vaccine plant workers ready to “parachute” into the next outbreak.

Vaccines Manufacturing
See All
UsernamePublicRestriction

Register